Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enfamil Growth Paces Strong Nutritionals Performance For Bristol-Myers

This article was originally published in The Tan Sheet

Executive Summary

Bristol-Myers Squibb's Enfamil infant formula brand posted sales growth of 24% to $175 mil. in the fourth quarter, contributing to a continued strong showing by the company's nutritional business. Quarterly sales in the U.S. increased 19% to $150 mil. For the year, Enfamil sales were up 13%, totaling $621 mil. worldwide, while U.S. sales rose 10% to $560 mil.
Advertisement

Related Content

Excedrin Migraine Full Migraine Indication Approved By FDA
Excedrin Migraine Full Migraine Indication Approved By FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS090807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel